



## ASX ANNOUNCEMENT

27 November 2013

### CAPITAL STRUCTURE

The Board of Cynata Therapeutics Limited (ASX: CYP) outlines the capital structure of the Company following the completion of the consolidation of the Company's securities approved by shareholders at the Annual General Meeting held on 29 October 2013, the issue of shares to the vendors of Cynata Incorporated and the issue of shares pursuant to the Prospectus lodged on 14 October 2013.

Class of Security	Number
Fully paid ordinary shares	44,906,701
Fully paid ordinary shares escrowed until 22 November 2014	10,000,001
<b>Total Shares</b>	<b>54,906,702</b>
Listed Options exercisable at \$0.20, expiring 31 December 2014 (CYPO)	11,164,701
Unlisted Options exercisable at \$0.40, expiring 27 September 2018 – escrowed for 24 months from date of reinstatement to official quotation (CYPAI)	5,000,000
Unlisted Options exercisable at \$0.40, expiring 9 September 2016 – escrowed for 24 months from date of reinstatement to official quotation (CYPAK)	500,000
Unlisted Options exercisable at \$3.98, expiring 30 November 2013 (CYP AO)	25,000

#### Dr Ross Macdonald

Managing Director & Chief Executive Officer  
+61 412 119 343

#### About Cynata Therapeutics Limited

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.